Profile data is unavailable for this security.
About the company
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
- Revenue in USD (TTM)0.00
- Net income in USD-15.84m
- Incorporated2019
- Employees5.00
- LocationGalecto Inc75 State Street, Suite 100BOSTON 02109United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://galecto.com/
More ▼
Mergers & acquisitions
| Acquired company | GLTO:NAQ since announced | Transaction value |
|---|---|---|
| Damora Therapeutics Inc | 350.91% | 1.31m |
Data delayed at least 15 minutes, as of Feb 10 2026 17:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onkure Therapeutics Inc | 0.00 | -81.21m | 34.68m | 46.00 | -- | 0.5221 | -- | -- | -12.78 | -12.78 | 0.00 | 4.90 | 0.00 | -- | -- | 0.00 | -107.93 | -48.73 | -115.20 | -53.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 31.94 | -- | 49.34 | -- |
| Tvardi Therapeutics Inc | 4.02m | -13.95m | 35.84m | 10.00 | -- | 1.29 | -- | 8.91 | -8.36 | -8.36 | 0.7709 | 2.97 | 0.0891 | -- | -- | 402,400.00 | -30.87 | -36.79 | -40.26 | -41.45 | 100.00 | -- | -346.55 | -155.60 | -- | -- | 0.00 | -- | -65.96 | -18.53 | 40.20 | -- | 125.35 | -- |
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 35.88m | 37.00 | -- | 2.60 | -- | 398.61 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 35.91m | 38.00 | 2.27 | -- | 1.35 | 0.2363 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Axe Compute Inc | 728.20k | -84.01m | 36.36m | 23.00 | -- | -- | -- | 49.94 | -120.02 | -120.66 | 1.29 | -100.94 | 0.1369 | 1.34 | 2.97 | 31,660.87 | -1,579.84 | -85.09 | -- | -113.42 | 50.24 | 61.31 | -11,536.93 | -1,267.27 | 0.0134 | -0.1392 | -- | -- | -0.2384 | 2.84 | 9.63 | -- | -18.60 | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 36.59m | 24.00 | -- | 3.53 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 36.86m | 64.00 | -- | -- | -- | 1.16 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 37.80m | 4.00 | -- | -- | -- | 50,403.00 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 38.06m | 64.00 | -- | 3.29 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| Galecto Inc | 0.00 | -15.84m | 38.28m | 5.00 | -- | 4.78 | -- | -- | -12.01 | -12.01 | 0.00 | 6.03 | 0.00 | -- | -- | 0.00 | -92.89 | -47.05 | -109.09 | -50.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 44.10 | -- | -- | -- |
| Veru Inc | 0.00 | -15.68m | 38.36m | 20.00 | -- | 1.91 | -- | -- | -1.07 | -1.55 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -34.75 | -47.51 | -44.42 | -59.79 | -- | -- | -- | -188.81 | -- | -- | 0.00 | -- | -- | -- | 55.53 | -- | -60.02 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 38.53m | 52.00 | -- | 10.46 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Liminatus Pharma Inc | 0.00 | -2.27m | 39.24m | -- | -- | -- | -- | -- | -0.0872 | -0.0872 | 0.00 | -0.0608 | 0.00 | -- | -- | -- | -77.46 | -- | -- | -- | -- | -- | -- | -- | -- | -12.30 | -- | -- | -- | -- | 28.85 | -- | -- | -- |
| Lisata Therapeutics Inc | 1.07m | -18.24m | 40.13m | 26.00 | -- | 2.29 | -- | 37.51 | -2.13 | -2.13 | 0.1246 | 1.98 | 0.0357 | -- | -- | 41,153.85 | -60.85 | -44.77 | -71.25 | -49.07 | -- | -- | -1,704.86 | -13,065.70 | -- | -- | 0.00 | -- | -- | -- | 4.10 | -- | -- | -- |
| INmune Bio Inc | 50.00k | -49.89m | 40.94m | 22.00 | -- | 1.61 | -- | 818.83 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Galecto Inc's reporting currency: US Dollar USD
45.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ikarian Capital LLCas of 30 Nov 2025 | 285.71k | 17.91% |
| Fidelity Management & Research Co. LLCas of 28 Nov 2025 | 238.88k | 14.98% |
| Point72 Asset Management LPas of 12 Nov 2025 | 100.00k | 6.27% |
| Connective Capital Management LLCas of 30 Sep 2025 | 26.96k | 1.69% |
| Two Sigma Investments LPas of 30 Sep 2025 | 20.30k | 1.27% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 15.04k | 0.94% |
| Sigma Planning Corp.as of 31 Dec 2025 | 14.50k | 0.91% |
| Virtu Americas LLCas of 30 Sep 2025 | 13.13k | 0.82% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.03k | 0.69% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 6.87k | 0.43% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
